Pharmaceutical Product Development LLC (PPD), Wilmington, NC, a global contract research organization (CRO), and NeoGenomics Laboratories Inc, Fort Myers, Fla, a provider of cancer-focused genetic testing services, are forming a strategic alliance to provide seamless and fully-integrated global pathology and molecular testing solutions to PPD’s pharmaceutical and biotechnology clients.
As part of the collaboration, NeoGenomics will provide a wide range of lab testing services to support PPD Laboratories’ oncology clinical trial activities in Asia, Europe, and the United States. Operationally, the partnership will leverage NeoGenomics’ sites in Europe and the United States, and both companies expect to jointly invest in PPD’s existing labs in China and Singapore. The companies will provide an integrated global IT solution, using PPD’s research use only Preclarus system to offer real-time visibility and analytics for informed decisionmaking during clinical trials.
Christopher Fikry, MD, PPD Laboratories.
Fully integrated with PPD’s CRO capabilities, PPD Laboratories offers comprehensive lab services, including bioanalytical, biomarkers, central lab, GMP, and vaccine sciences. NeoGenomics provides a comprehensive oncology-focused testing menu to support physicians with cancer diagnosis and treatment and assist pharmaceutical clients with clinical trials and drug development. NeoGenomics maintains a network of CAP-accredited, CLIA-licensed facilities across the United States.
The new collaboration focuses on centralized pathology review as well as specialty lab services, including cytogenetics, flow cytometry, fluorescence in situ hybridization, immunohistochemistry, molecular assays, and next-generation sequencing, as well as NeoGenomics’ proprietary multiplexing methodology, MultiOmyx.
Together, the companies will provide a comprehensive offering for the development of companion diagnostics, from biomarker discovery through regulatory approval and commercialization. Additionally, the teams are committed to leveraging their combined data assets to find more efficient methods of identifying appropriate patients for oncology trials.
Douglas VanOort, NeoGenomics.
“NeoGenomics has world-class scientific talent, significant oncology trial experience, and a broad geographic presence that will allow us to further enhance our global laboratory services for oncology trials,” says Christopher Fikry, MD, executive vice president of PPD Laboratories.“ Working with NeoGenomics will enable us to jointly provide a premier global oncology and specialty laboratory solution for our customers.”
“We are pleased to be joining PPD in this important strategic alliance and look forward to collaborating with the many scientific professionals on their team,” says Douglas VanOort, CEO of NeoGenomics.“ Our company is committed to saving lives by improving patient care through communication, accuracy, reliability, and efficiency. That commitment aligns closely with PPD’s mission and purpose to help its customers deliver life-changing therapies that improve health.”
To learn more, visit PPD Laboratories and NeoGenomics.
